Aclarion CEO to Pitch NOCISCAN at LSI USA 2026 Amid Chronic Back Pain Market Push
Event summary
- Aclarion CEO Brent Ness to attend LSI USA 2026 (March 16-20, 2026) to meet investors and partners.
- NOCISCAN platform leverages AI and biomarkers to identify chronic low back pain sources.
- Company seeks to advance commercialization of its MR spectroscopy technology.
- LSI USA 2026 is a key MedTech/HealthTech innovation conference in Dana Point, CA.
The big picture
Aclarion's participation in LSI USA 2026 underscores the growing intersection of AI and diagnostic imaging in chronic pain management. The company's focus on biomarker-driven solutions positions it within a competitive MedTech landscape where precision diagnostics are increasingly valued. Success will depend on both technological validation and strategic partnerships formed at events like this one.
What we're watching
- Commercialization Pace
- How quickly Aclarion can scale NOCISCAN adoption among physicians.
- Investor Interest
- Whether LSI USA 2026 meetings yield new partnerships or funding.
- Regulatory Clarity
- The timeline for potential regulatory approvals expanding NOCISCAN's use.
Our editorial coverage: